Pfizer and BioNTech report positive data in trial of omicron-targeting bivalent booster in individuals aged 18 and olderMarket Watch • 10/13/22
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and OlderBusiness Wire • 10/13/22
Pfizer, BioNTech stocks surge after FDA grants emergency use of BA.4, BA.5 adapted booster shots in childrenMarket Watch • 10/12/22
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of AgeGlobeNewsWire • 10/12/22
BioNTech and Australia's State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing FacilityGlobeNewsWire • 10/06/22
Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11Market Watch • 09/26/22
Pfizer and BioNTech seek FDA EUA for omicron-targeting booster for use in children aged 5 to 11Market Watch • 09/26/22
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of AgeBusiness Wire • 09/26/22
Moderna, BioNTech, and Novavax plunge after President Biden says the COVID-19 pandemic 'is over'Business Insider • 09/19/22
Vaccine stocks Pfizer, BioNTech, Moderna and Novavax slide after Biden says pandemic is overMarket Watch • 09/19/22
Pfizer, BioNTech COVID vaccine gets CHMP recommendation for 'full' MA for all indicationsMarket Watch • 09/16/22